

LAMPIRAN

Lampiran 1. Surat *Ethical Clearance*



KOMITE ETIK PENELITIAN KESEHATAN
HEALTH RESEARCH ETHICS COMMITTEE
RSI SULTAN AGUNG
KEPK RSI SULTAN AGUNG

KETERANGAN LAYAK ETIK
DESCRIPTION OF ETHICAL EXEMPTION
"ETHICAL EXEMPTION"

No. 47/EC/KEPK/2020

Protokol penelitian yang diusulkan oleh :
The research protocol proposed by

Peneliti utama : RIZKA JULIANISA
Principal In Investigator

Nama Institusi : UNIVERSITAS ISLAM SULTAN AGUNG
Name of Institution

Dengan Judul
Title

**"EVALUASI EFEK SAMPING PASCA OPERASI ORTOPEDI SETELAH PENGGUNAAN
INJEKSI KETOROLAC DI RS ISLAM SULTAN AGUNG SEMARANG"**


***"Evaluation of Post-Orthopaedic Side Effect Following Use of Ketorolac Injection at Islamic Sultan Agung
Semarang Hospital"***

Dinyatakan layak etik sesuai 7(tujuh) Standar WHO 2011, yaitu 1) Nilai Sosial, 2) Nilai Ilmiah, 3) Pemerataan Beban dan Manfaat, 4) Risiko, 5) Bujukan/Eksploitasi, 6) Kerahasiaan dan Privacy, dan 7) Persetujuan Setelah Penjelasan, yang merujuk pada Pedoman CIOMS 2016. Hal ini seperti yang ditunjukkan oleh terpenuhinya indikator setiap standar.

Declared to be ethically appropriate in accordance to 7 (seven) WHO 2011 Standards, 1)Social Values, 2)Scientific Values, 3)Equitable Assessment and Benefits, 4)Risks, 5)Persuasion/Exploitation, 6)Confidentiality and Privacy, and 7)Informed Consent, referring to the 2016 CIOMS Guidelines. This is as indicated by the fulfillment of the indicators of each standard.

Pernyataan Laik Etik ini berlaku selama kurun waktu tanggal 25 September 2020 sampai dengan tanggal 25 September 2021.

This declaration of ethics applies during the period September 25, 2020 until September 25, 2021.

September 25, 2020
Professor and Chairperson

YAYASAN BADAN WAKAF SULTAN AGUNG
RSI SULTAN AGUNG
ISLAMIC TEACHING HOSPITAL
Rumah Sakit Sesuai Prinsip Syariah
SEMARANG dr. Muhammad Aziz Rosidi

www.rsisultanagung.co.id

Lampiran 2. Daftar Pasien Pasca Operasi Ortopedi

Lampiran 1. Daftar pasien pasca operasi ortopedi tahun 2019 di RS Islam Sultan Agung Semarang												
No	No RM	Usia	Jenis	Obat			Efek Samping				Total	Lama
	Jenis Kel	Tahun	Operasi	Nama	Dosis	Ket.	1	2	3	4	Kejadian	Pakai
1	388045	33	Fraktur	Ketorolac	3x30 mg	IV					0	3 hari
	P		Forearm	Ondansetron	4 mg	IV						
2	385393	39	Fraktur	Ketorolac	3x30 mg	IV	✓	✓	✓	✓	4	6 hari
	L		Tibia	Ranitidin	2x1A	IV						
				Ceftriaxone	2x1 gr	IV						
3	381090	23	Fraktur	Ketorolac	3x30 mg	IV	✓				1	3 hari
	L		Forearm	Ranitidin	2x1A	IV						
				Cefixime	2x1	PO						
4	267539	56	Fraktur	Ketorolac	3x30 mg	IV		✓			1	2 hari
	P		Femur	Ranitidin	2x1A	IV						
5	377080	41	Fraktur	Ketorolac	2x30 mg	IV	✓	✓			2	5 hari
	L		Femur	Cefotaxime	2x1 gr	IV						
6	384028	59	Fraktur	Ketorolac	3x30 mg	IV				✓	1	3 hari
	P		Forearm	Cefotaxime	2x1 gr	IV						
7	254872	56	Fraktur	Ketorolac	3x30 mg	IV	✓	✓			2	4 hari
	P		Femur	Ceftriaxone	2x1 gr	IV						
8	383302	60	Fraktur	Ketorolac	2x30 mg	IV					0	2 hari
	L		Forearm	Cefotaxime	2x1 gr	IV						
9	393853	58	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	P		Femur	Ranitidin	3x1 A	IV						
				Ceftriaxone	2x1 gr	IV						
10	377403	28	Fraktur	Ketorolac	3x30 mg	IV		✓			1	5 hari

	P		Forearm	Ranitidin	2x1A	IV						
11	378254	39	Fraktur	Ketorolac	3x30 mg	IV			✓	1	4 hari	
	P		Tibia	Ranitidin	2x1 A	IV						
				Ceftriaxone	2x1 gr	IV						
12	380685	38	Fraktur	Ketorolac	3x30 mg	IV		✓		1	4 hari	
	P		Femur	Ranitidin	2x1 A	IV						
13	253776	27	Fraktur	Ketorolac	3x30 mg	IV			✓	1	3 hari	
	L		Femur	Ranitidin	2x1 A	IV						
				Cefotaxime	2x1 gr	IV						
14	376520	43	Fraktur	Ketorolac	2x30 mg	IV		✓	✓	2	5 hari	
	L		Forearm	Cefotaxime	2x1 gr	IV						
15	377867	24	Fraktur	Ketorolac	3x30 mg	IV	✓	✓		2	4 hari	
	L		Femur	Ranitidin	2x1 A	IV						
				Ceftriaxone	2x1 gr	IV						
16	379079	53	Fraktur	Ketorolac	3x30 mg	IV	✓	✓		2	5 hari	
	P		Femur	Ranitidin	2x1 A	IV						
				Ceftriaxone	2x1 gr	IV						
17	336740	29	Fraktur	Ketorolac	3x30 mg	IV			✓	1	3 hari	
	L		Femur									
18	387128	19	Fraktur	Ketorolac	2x30 mg	IV			✓	1	4 hari	
	L		Femur	Cefotaxime	2x1 gr	IV						
19	370590	52	Fraktur	Ketorolac	2x30 mg	IV				0	2 hari	
	P		Femur	Ondansetron	4 mg	IV						
20	095429	54	Fraktur	Ketorolac	2x30 mg	IV	✓	✓		2	2 hari	
	L		Femur									

21	372850	39	Fraktur	Ketorolac	2x30 mg	IV	✓	✓		2	4 hari
	P		Forearm	Cefotaxime	2x1 gr	IV					
22	099709	23	Fraktur	Ketorolac	2x30 mg	IV		✓		1	3 hari
	P		Forearm	Cefotaxime	2x1 gr	IV					
				Amoxicillin	3x1	PO					
23	388278	45	Fraktur	Ketorolac	2x30 mg	IV	✓			1	3 hari
	L		Forearm	Cefotaxime	2x1 gr	IV					
24	376520	43	Fraktur	Ketorolac	2x30 mg	IV		✓		1	5 hari
	L		Forearm	Cefotaxime	2x1 gr	IV					
25	396051	26	Fraktur	Ketorolac	2x30 mg	IV			✓	2	2 hari
	L		Femur	Mecobalamin	1x2 A	IV					
26	379865	55	Fraktur	Ketorolac	3x30 mg	IV			✓	1	3 hari
	L		Femur	Ceftriaxone	2x1 gr	IV					
				Ranitidin	2x1 A	IV					
27	223931	25	Fraktur	Ketorolac	3x30 mg	IV				0	1 hari
	P		Forearm	Sharox	3x750	IV					
28	379176	38	Fraktur	Ketorolac	3x30 mg	IV			✓	1	2 hari
	L		Forearm	Sharox	3x750	IV					
29	336175	38	Fraktur	Ketorolac	2x30 mg	IV		✓		1	1 hari
	L		Forearm	Bactesyn	3x1	IV					
30	164653	51	Fraktur	Ketorolac	2x30 mg	IV				0	2 hari
	P		Forearm	Omeprazole	2x1	IV					
				Ciprofloxacin	2x1	PO					
31	383389	37	Fraktur	Ketorolac	3x30 mg	IV				0	2 hari
	P		Tibia	Ranitidin	3x1 A	IV					

32	114774	30	Fraktur	Ketorolac	3x30 mg	IV					0	3 hari
	P		Forearm	Ranitidin	2x1 A	IV						
33	399580	30	Fraktur	Ketorolac	3x30 mg	IV		✓			1	3 hari
	P		Forearm	Ceftriaxone	2x1	IV						
				As. Tranexamat	3x1	IV						
				Vitamin C	2x1	IV						
34	002254	57	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	P		Femur	Ranitidin	3x1 A	IV						
				Cefixime	2x200 gr	PO						
35	363763	43	Fraktur	Ketorolac	3x30 mg	IV		✓			1	3 hari
	P		Femur	Ranitidin	2x1 A	IV						
				Ceftriaxone	2x1 gr	IV						
36	144999	43	Fraktur	Ketorolac	2x30 mg	IV		✓			1	3 hari
	L		Femur	Sharox	3x750 mg	IV						
37	253821	35	Fraktur	Ketorolac	3X30 mg	IV				✓	1	3 hari
	P		Forearm	Sharox	3x750 mg	IV						
38	383106	49	Fraktur	Ketorolac	3x30 mg	IV			✓		1	2 hari
	L		Tibia									
39	385049	39	Fraktur	Ketorolac	3x30 mg	IV					0	4 hari
	L		Tibia	Ranitidin	3x1 A	IV						
40	049762	63	Fraktur	Ketorolac	3x30 mg	IV			✓	✓	2	3 hari
	L		Femur									
41	161451	39	Fraktur	Ketorolac	3x30 mg	IV					0	1 hari
	L		Tibia	Ranitidin	2x1 A	IV						

				Ceftriaxone	2x1 gr	IV							
42	384011	24	Fraktur	Ketorolac	3x30 mg	IV	✓					1	2 hari
	L		Femur	Ceftriaxone	2x1 gr	IV							
43	049762	63	Fraktur	Ketorolac	3x30 mg	IV				✓		1	2 hari
	L		Forearm	Sharox	3x750 mg	IV							
44	399198	47	Fraktur	Ketorolac	3x30 mg	IV	✓	✓	✓			3	4 hari
	L		Forearm	Triject	2x1 gr	IV							
				Fortison	1x1	IV							
45	049762	63	Fraktur	Ketorolac	3x30 mg	IV				✓		1	2 hari
	L		Forearm	Sharox	3x750 mg	IV							
46	257376	56	Fraktur	Ketorolac	3x30 mg	IV							1 hari
	L		Tibia	Sharox	3x750	IV							
47	372762	36	Fraktur	Ketorolac	3x30 mg	IV						0	1 hari
	P		Femur	Broadced	2x1	IV							
48	296044	45	Fraktur	Ketorolac	3x30 mg	IV						0	1 hari
	L		Tibia										
49	379288	46	Fraktur	Ketorolac	3x30 mg	IV		✓				1	4 hari
	L		Tibia	Ranitidin	2x1 A	IV							
				Cefspan	2x1 A	PO							
50	336695	36	Fraktur	Ketorolac	3x30 mg	IV			✓			1	4 hari
	P		Tibia	Broadced	2x1	IV							
51	374373	47	Fraktur	Ketorolac	3x30 mg	IV						0	1 hari
	L		Forearm	Ranitidin	2x1 A	IV							
				Cefazolin	3x1 gr	IV							

52	375960	29	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	L		Femur									
53	370967	41	Fraktur	Ketorolac	3x30 mg	IV		✓			1	3 hari
	P		Femur	Ranitidin	2x1 A	IV						
54	387325	23	Fraktur	Ketorolac	3x30 mg	IV		✓			1	3 hari
	L		Tibia	Ranitidin	3x1 A	IV						
				Cefixime	2x1	PO						
55	259473	46	Fraktur	Ketorolac	3x30 mg	IV		✓			1	2 hari
	L		Forearm	Sharox	3x750 mg	IV						
				Kalnex	3x500 mg	PO						
56	376953	42	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	L		Forearm	Ceftriaxone	2x1	IV						
57	017691	19	Fraktur	Ketorolac	3x30 mg	IV			✓		1	2 hari
	L		Tibia	Sharox	3x750 mg	IV						
58	386001	50	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	L		Forearm	Ranitidin	3x1 A	IV						
				Cefixime	2x100 mg	PO						
59	017691	19	Fraktur	Ketorolac	3x30 mg	IV			✓		1	2 hari
	L		Tibia	L-Alamin	1x1							
60	386661	21	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	L		Tibia	Ranitidin	2x1 A	IV						
				Ciprofloxacin	2x1	PO						
61	387721	34	Fraktur	Ketorolac	3x30 mg	IV					0	1 hari
	P		Femur	Ranitidin	3x1 A	IV						
				Cefixime	2x100	PO						

					mg							
62	399375	53	Fraktur	Ketorolac	3x30 mg	IV		✓			1	3 hari
	P		Femur	Omeprazole	2x1							
				Ciprofloxacin	2x1	PO						
63	375159	20	Fraktur	Ketorolac	3x30 mg	IV		✓			1	6 hari
	L		Tibia	Ranitidin	2x1 A	IV						
				Cefxon	2x1 gr	IV						
64	235022	30	Fraktur	Ketorolac	3x30 mg	IV					0	1 hari
	L		Tibia	Kalnex	3x1	IV						
65	373691	52	Fraktur	Ketorolac	3x30 mg	IV		✓			1	3 hari
	P		Femur	Sharox	3x750 mg	IV						
66	392263	31	Fraktur	Ketorolac	3x30 mg	IV		✓			1	2 hari
	L		Forearm	Ranitidin	2x1 A	IV						
67	379814	26	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	L		Forearm	Ranitidin	2x1 A	IV						
68	365565	20	Fraktur	Ketorolac	3x30 mg	IV		✓	✓		2	4 hari
	P		Forearm	Lansoprazole	2x1							
69	376675	21	Fraktur	Ketorolac	3x30 mg	IV	✓	✓	✓	✓	4	6 hari
	L		Femur	Ciprofloxacin	2x750 mg	IV						
				Kalnex	3x1	IV						
70	385718	24	Fraktur	Ketorolac	3x30 mg	IV		✓		✓	2	2 hari
	L		Forearm	Sharox	3x750 mg	IV						
71	050947	48	Fraktur	Ketorolac	3x30 mg	IV				✓	1	1 hari
	L		Tibia	Humalog	3x1	IV						

				Ampicillin	3x1,5 gr	IV							
72	054734	36	Fraktur	Ketorolac	3x30 mg	IV					0	3 hari	
	L		Forearm	Ranitidin	2x1 A	IV							
73	377729	52	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari	
	L		Tibia	Ranitidin	3x1 A	IV							
74	383866	23	Fraktur	Ketorolac	3x30 mg	IV					0	1 hari	
	L		Femur	Ranitidin	2x1 A	IV							
				Ceftriaxone	2x1	IV							
75	259168	54	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari	
	L		Femur	Ranitidin	2x1 A	IV							
				Cefixime	2x200 gr	PO							
76	290407	57	Fraktur	Ketorolac	3x30 mg	IV				✓	1	1 hari	
	L		Tibia	Moxifloxacin	1x1	IV							
77	162115	55	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari	
	L		Tibia	Sharox	3x750 mg	IV							
78	387898	23	Fraktur	Ketorolac	3x30 mg	IV	✓	✓			2	5 hari	
	L		Femur	Moxifloxacin	1x1	IV							
				Methylpred	1x1								
79	367665	33	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari	
	P		Tibia	Ranitidin	3x1 A	IV							
				Cefxon	2x1	IV							
80	391743	41	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari	
	P		Femur	Sharox	3x750 mg	IV							
81	379865	55	Fraktur	Ketorolac	3x30 mg	IV					0	3 hari	
	P		Femur	Ranitidin	3x1 A	IV							

				Cefxon	2x1	IV						
82	384220	25	Fraktur	Ketorolac	3x30 mg	IV				✓	1	2 hari
	L		Femur	Sharox	3x750 mg	IV						
				Kalnex	3x1	IV						
83	376531	39	Fraktur	Ketorolac	3x30 mg	IV			✓		1	2 hari
	L		Forearm	Sharox	3x750 mg	IV						
				Gabaxa	1x1	IV						
84	176958	47	Fraktur	Ketorolac	3x30 mg	IV					0	2 hari
	L		Tibia	Ranitidin	2x750 mg	IV						
				Cefspan	2x1	PO						
85	041838	34	Fraktur	Ketorolac	3x30 mg	IV	✓	✓	✓		3	3 hari
	P		Tibia	Ranitidin	2x1 A	IV						
86	383876	27	Fraktur	Ketorolac	3x30 mg	IV		✓			1	5 hari
	L		Femur	Ranitidin	2x1 A	IV						
87	385086	58	Fraktur	Ketorolac	3x30 mg	IV		✓			1	4 hari
	L		Tibia	Ranitidin	3x1 A	IV						
				Cefxon	2x1	IV						
88	380903	20	Fraktur	Ketorolac	3x30 mg	IV					0	3 hari
	L		Femur	Ranitidin	3x1 A	IV						
89	380903	20	Fraktur	Ketorolac	3x30 mg	IV			✓		1	2 hari
	L		Femur	Ranitidin	3x1 A	IV						
90	381982	36	Fraktur	Ketorolac	3x30 mg	IV			✓		1	2 hari
	L		Tibia	Sharox	1,5 gr	IV						
91	387325	23	Fraktur	Ketorolac	3x30 mg	IV		✓			1	2 hari

	L		Femur	Ranitidin	3x1 A	IV							
				Cefspan	2x1	PO							
92	375242	45	Fraktur	Ketorolac	3x30 mg	IV					0		1 hari
	P		Femur	Humalog	3x1	IV							
93	381982	35	Fraktur	Ketorolac	3x30 mg	IV					0		2 hari
	L		Tibia	Ranitidin	3x1 A	IV							
94	077667	55	Fraktur	Ketorolac	3x30 mg	IV					0		2 hari
	P		Femur	Moxifloxacin	1x1	IV							
95	108032	30	Fraktur	Ketorolac	3x30 mg	IV			✓		1		3 hari
	L		Femur	Ranitidin	3x1 A	IV							
96	381982	30	Fraktur	Ketorolac	3x30 mg	IV					0		1 hari
	L		Femur	Ranitidin	2x1 A	IV							
				Cefxon	2x1	IV							
97	369801	53	Fraktur	Ketorolac	3x30mg	IV			✓		1		2 hari
	L		Forearm	Ciprofloxacin	3x400mg	PO							
98	242315	26	Fraktur	Ketorolac	3x30 mg	IV			✓		1		3 hari
	P		Femur	Ranitidin	2x1 A	IV							

Keterangan:

1. Mual
2. Muntah
3. Pusing
4. Kembung

Lampiran 3. Frekuensi Karakteristik Pasien

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-Laki	63	64.3	64.3	64.3
	Perempuan	35	35.7	35.7	100.0
	Total	98	100.0	100.0	

Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	18-40 tahun	54	55.1	55.1	55.1
	41-65 tahun	44	44.9	44.9	100.0
	Total	98	100.0	100.0	

Dosis

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	30 mg tiap 12 jam	13	13.3	13.3	13.3
	30 mg tiap 8 jam	85	86.7	86.7	100.0
	Total	98	100.0	100.0	

Lama Penggunaan

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	≤5 hari	95	96.9	96.9	96.9
	>5 hari	3	3.1	3.1	100.0
	Total	98	100.0	100.0	

Diagnosa

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Fraktur Femur	41	41.8	41.8	41.8
	Fraktur Tibia	26	26.5	26.5	68.4
	Fraktur Forearm	31	31.6	31.6	100.0
	Total	98	100.0	100.0	

Lampiran 4. Frekuensi Efek Samping yang terjadi pada Pasien Pasca Operasi Ortopedi

Mual

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	14	14.3	14.3	14.3
	Tidak	84	85.7	85.7	100.0
	Total	98	100.0	100.0	

Muntah

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	30	30.6	30.6	30.6
	Tidak	68	69.4	69.4	100.0
	Total	98	100.0	100.0	

Pusing

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	20	20.4	20.4	20.4
	Tidak	78	79.6	79.6	100.0
	Total	98	100.0	100.0	

Kembung

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	19	19.4	19.4	19.4
	Tidak	79	80.6	80.6	100.0
	Total	98	100.0	100.0	

Efek Samping Obat

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tanpa Efek Samping	36	36.7	36.7	36.7
	Dengan Efek Samping	62	63.3	63.3	100.0
	Total	98	100.0	100.0	

Lampiran 5. Analisis Uji *Chi-Square*

Jenis Kelamin * Mual

Crosstab					
			Mual		Total
			Ya	Tidak	
Jenis Kelamin	Laki-Laki	Count	10	53	63
		% within Jenis Kelamin	15.9%	84.1%	100.0%
		% within Mual	71.4%	63.1%	64.3%
		% of Total	10.2%	54.1%	64.3%
	Perempuan	Count	4	31	35
		% within Jenis Kelamin	11.4%	88.6%	100.0%
		% within Mual	28.6%	36.9%	35.7%
		% of Total	4.1%	31.6%	35.7%
Total	Count	14	84	98	
	% within Jenis Kelamin	14.3%	85.7%	100.0%	
	% within Mual	100.0%	100.0%	100.0%	
	% of Total	14.3%	85.7%	100.0%	

Chi-Square Tests					
	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.363 ^a	1	.547	.765	.390
Continuity Correction ^b	.091	1	.763		
Likelihood Ratio	.374	1	.541		
Fisher's Exact Test					
Linear-by-Linear Association	.359	1	.549		
N of Valid Cases	98				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.00.

b. Computed only for a 2x2 table

Jenis Kelamin * Muntah

Crosstab			Muntah		Total
			Ya	Tidak	
Jenis Kelamin	Laki-Laki	Count	17	46	63
		% within Jenis Kelamin	27.0%	73.0%	100.0%

		% within Muntah	56.7%	67.6%	64.3%
		% of Total	17.3%	46.9%	64.3%
	Perempuan	Count	13	22	35
		% within Jenis Kelamin	37.1%	62.9%	100.0%
		% within Muntah	43.3%	32.4%	35.7%
		% of Total	13.3%	22.4%	35.7%
Total		Count	30	68	98
		% within Jenis Kelamin	30.6%	69.4%	100.0%
		% within Muntah	100.0%	100.0%	100.0%
		% of Total	30.6%	69.4%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.093 ^a	1	.296	.362	.206
Continuity Correction ^b	.667	1	.414		
Likelihood Ratio	1.078	1	.299		
Fisher's Exact Test					
Linear-by-Linear Association	1.082	1	.298		
N of Valid Cases	98				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10.71.

b. Computed only for a 2x2 table

Jenis Kelamin * Pusing

Crosstab

			Pusing		Total
			Ya	Tidak	
Jenis Kelamin	Laki-Laki	Count	16	47	63
		% within Jenis Kelamin	25.4%	74.6%	100.0%
		% within Pusing	80.0%	60.3%	64.3%
		% of Total	16.3%	48.0%	64.3%
	Perempuan	Count	4	31	35
		% within Jenis Kelamin	11.4%	88.6%	100.0%
		% within Pusing	20.0%	39.7%	35.7%
		% of Total	4.1%	31.6%	35.7%
Total		Count	20	78	98

% within Jenis Kelamin	20.4%	79.6%	100.0%
% within Pusing	100.0%	100.0%	100.0%
% of Total	20.4%	79.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	2.703 ^a	1	.100	.122	.081
Continuity Correction ^b	1.911	1	.167		
Likelihood Ratio	2.903	1	.088		
Fisher's Exact Test					
Linear-by-Linear Association	2.675	1	.102		
N of Valid Cases	98				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.14.

b. Computed only for a 2x2 table

Jenis Kelamin * Kambung

Crosstab

			Kambung		Total
			Ya	Tidak	
Jenis Kelamin	Laki-Laki	Count	14	49	63
		% within Jenis Kelamin	22.2%	77.8%	100.0%
		% within Kambung	73.7%	62.0%	64.3%
		% of Total	14.3%	50.0%	64.3%
	Perempuan	Count	5	30	35
		% within Jenis Kelamin	14.3%	85.7%	100.0%
		% within Kambung	26.3%	38.0%	35.7%
		% of Total	5.1%	30.6%	35.7%
Total	Count		19	79	98
	% within Jenis Kelamin		19.4%	80.6%	100.0%
	% within Kambung		100.0%	100.0%	100.0%
	% of Total		19.4%	80.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.907 ^a	1	.341		

Continuity Correction ^b	.470	1	.493		
Likelihood Ratio	.941	1	.332		
Fisher's Exact Test				.429	.250
Linear-by-Linear Association	.898	1	.343		
N of Valid Cases	98				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.79.

b. Computed only for a 2x2 table

Usia Pasien * Mual

Crosstab

			Mual		Total
			Ya	Tidak	
Usia Pasien	18-25	Count	5	15	20
		Expected Count	2.9	17.1	20.0
		% within Usia Pasien	25.0%	75.0%	100.0%
		% within Mual	35.7%	17.9%	20.4%
		% of Total	5.1%	15.3%	20.4%
	26-45	Count	5	39	44
		Expected Count	6.3	37.7	44.0
		% within Usia Pasien	11.4%	88.6%	100.0%
		% within Mual	35.7%	46.4%	44.9%
		% of Total	5.1%	39.8%	44.9%
	46-65	Count	4	30	34
		Expected Count	4.9	29.1	34.0
		% within Usia Pasien	11.8%	88.2%	100.0%
		% within Mual	28.6%	35.7%	34.7%
		% of Total	4.1%	30.6%	34.7%
Total		Count	14	84	98
		Expected Count	14.0	84.0	98.0
		% within Usia Pasien	14.3%	85.7%	100.0%
		% within Mual	100.0%	100.0%	100.0%
		% of Total	14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	2.358 ^a	2	.308

Likelihood Ratio	2.103	2	.349
Linear-by-Linear Association	1.399	1	.237
N of Valid Cases	98		

a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 2.86.

Usia Pasien * Muntah

Crosstab

			Muntah		Total
			Ya	Tidak	
Usia Pasien	18-25	Count	8	12	20
		Expected Count	6.1	13.9	20.0
		% within Usia Pasien	40.0%	60.0%	100.0%
		% within Muntah	26.7%	17.6%	20.4%
		% of Total	8.2%	12.2%	20.4%
	26-45	Count	13	31	44
		Expected Count	13.5	30.5	44.0
		% within Usia Pasien	29.5%	70.5%	100.0%
		% within Muntah	43.3%	45.6%	44.9%
		% of Total	13.3%	31.6%	44.9%
	46-65	Count	9	25	34
		Expected Count	10.4	23.6	34.0
		% within Usia Pasien	26.5%	73.5%	100.0%
		% within Muntah	30.0%	36.8%	34.7%
		% of Total	9.2%	25.5%	34.7%
	Total	Count	30	68	98
		Expected Count	30.0	68.0	98.0
		% within Usia Pasien	30.6%	69.4%	100.0%
		% within Muntah	100.0%	100.0%	100.0%
		% of Total	30.6%	69.4%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	1.128 ^a	2	.569
Likelihood Ratio	1.097	2	.578
Linear-by-Linear Association	.967	1	.325

N of Valid Cases	98	
------------------	----	--

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.12.

Usia Pasien * Pusing

Crosstab

			Pusing		Total
			Ya	Tidak	
Usia Pasien	18-25	Count	5	15	20
		Expected Count	4.1	15.9	20.0
		% within Usia Pasien	25.0%	75.0%	100.0%
		% within Pusing	25.0%	19.2%	20.4%
		% of Total	5.1%	15.3%	20.4%
	26-45	Count	11	33	44
		Expected Count	9.0	35.0	44.0
		% within Usia Pasien	25.0%	75.0%	100.0%
		% within Pusing	55.0%	42.3%	44.9%
		% of Total	11.2%	33.7%	44.9%
	46-65	Count	4	30	34
		Expected Count	6.9	27.1	34.0
		% within Usia Pasien	11.8%	88.2%	100.0%
		% within Pusing	20.0%	38.5%	34.7%
		% of Total	4.1%	30.6%	34.7%
	Total	Count	20	78	98
		Expected Count	20.0	78.0	98.0
		% within Usia Pasien	20.4%	79.6%	100.0%
		% within Pusing	100.0%	100.0%	100.0%
		% of Total	20.4%	79.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	2.395 ^a	2	.302
Likelihood Ratio	2.569	2	.277
Linear-by-Linear Association	1.743	1	.187
N of Valid Cases	98		

a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.08.

Usia Pasien * Kambung

Crosstab

			Kambung		Total
			Ya	Tidak	
Usia Pasien	18-25	Count	5	15	20
		Expected Count	3.9	16.1	20.0
		% within Usia Pasien	25.0%	75.0%	100.0%
		% within Kambung	26.3%	19.0%	20.4%
		% of Total	5.1%	15.3%	20.4%
	26-45	Count	6	38	44
		Expected Count	8.5	35.5	44.0
		% within Usia Pasien	13.6%	86.4%	100.0%
		% within Kambung	31.6%	48.1%	44.9%
		% of Total	6.1%	38.8%	44.9%
	46-65	Count	8	26	34
		Expected Count	6.6	27.4	34.0
		% within Usia Pasien	23.5%	76.5%	100.0%
		% within Kambung	42.1%	32.9%	34.7%
		% of Total	8.2%	26.5%	34.7%
	Total	Count	19	79	98
		Expected Count	19.0	79.0	98.0
		% within Usia Pasien	19.4%	80.6%	100.0%
		% within Kambung	100.0%	100.0%	100.0%
		% of Total	19.4%	80.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	1.707 ^a	2	.426
Likelihood Ratio	1.747	2	.417
Linear-by-Linear Association	.010	1	.921
N of Valid Cases	98		

a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 3.88.

Dosis * Mual

Crosstab

			Mual		Total
			Ya	Tidak	
Dosis	30 mg tiap 12 jam	Count	4	9	13
		% within Dosis	30.8%	69.2%	100.0%
		% within Mual	28.6%	10.7%	13.3%
		% of Total	4.1%	9.2%	13.3%
	30 mg tiap 8 jam	Count	10	75	85
		% within Dosis	11.8%	88.2%	100.0%
		% within Mual	71.4%	89.3%	86.7%
		% of Total	10.2%	76.5%	86.7%
Total	Count		14	84	98
	% within Dosis		14.3%	85.7%	100.0%
	% within Mual		100.0%	100.0%	100.0%
	% of Total		14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	3.326 ^a	1	.068	.088	.088
Continuity Correction ^b	1.955	1	.162		
Likelihood Ratio	2.759	1	.097		
Fisher's Exact Test					
Linear-by-Linear Association	3.292	1	.070		
N of Valid Cases	98				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 1.86.

b. Computed only for a 2x2 table

Dosis * Muntah

Crosstab

			Muntah		Total
			Ya	Tidak	
Dosis	30 mg tiap 12 jam	Count	6	7	13
		% within Dosis	46.2%	53.8%	100.0%
		% within Muntah	20.0%	10.3%	13.3%

		% of Total	6.1%	7.1%	13.3%
30 mg tiap 8 jam	Count		24	61	85
	% within Dosis		28.2%	71.8%	100.0%
	% within Muntah		80.0%	89.7%	86.7%
	% of Total		24.5%	62.2%	86.7%
Total	Count		30	68	98
	% within Dosis		30.6%	69.4%	100.0%
	% within Muntah		100.0%	100.0%	100.0%
	% of Total		30.6%	69.4%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.704 ^a	1	.192	.209	.162
Continuity Correction ^b	.965	1	.326		
Likelihood Ratio	1.606	1	.205		
Fisher's Exact Test					
Linear-by-Linear Association	1.687	1	.194		
N of Valid Cases	98				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.98.

b. Computed only for a 2x2 table

Dosis * Pusing

Crosstab

			Pusing		Total
			Ya	Tidak	
Dosis	30 mg tiap 12 jam	Count	3	10	13
		% within Dosis	23.1%	76.9%	100.0%
		% within Pusing	15.0%	12.8%	13.3%
		% of Total	3.1%	10.2%	13.3%
	30 mg tiap 8 jam	Count	17	68	85
		% within Dosis	20.0%	80.0%	100.0%
		% within Pusing	85.0%	87.2%	86.7%
		% of Total	17.3%	69.4%	86.7%
Total		Count	20	78	98
		% within Dosis	20.4%	79.6%	100.0%

% within Pusing	100.0%	100.0%	100.0%
% of Total	20.4%	79.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.066 ^a	1	.798		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.064	1	.800		
Fisher's Exact Test				.725	.522
Linear-by-Linear Association	.065	1	.799		
N of Valid Cases	98				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.65.

b. Computed only for a 2x2 table

Dosis * Kembung

Crosstab

			Kembung		Total
			Ya	Tidak	
Dosis	30 mg tiap 12 jam	Count	1	12	13
		% within Dosis	7.7%	92.3%	100.0%
		% within Kembung	5.3%	15.2%	13.3%
		% of Total	1.0%	12.2%	13.3%
	30 mg tiap 8 jam	Count	18	67	85
		% within Dosis	21.2%	78.8%	100.0%
		% within Kembung	94.7%	84.8%	86.7%
		% of Total	18.4%	68.4%	86.7%
Total		Count	19	79	98
		% within Dosis	19.4%	80.6%	100.0%
		% within Kembung	100.0%	100.0%	100.0%
		% of Total	19.4%	80.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	1.312 ^a	1	.252		
Continuity Correction ^b	.591	1	.442		

Likelihood Ratio	1.573	1	.210		
Fisher's Exact Test				.453	.230
Linear-by-Linear Association	1.298	1	.255		
N of Valid Cases	98				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.52.

b. Computed only for a 2x2 table

Lama Penggunaan * Mual

Crosstab

			Mual		Total
			Ya	Tidak	
Lama Penggunaan ≤5 hari	Count		12	83	95
	% within Lama Penggunaan		12.6%	87.4%	100.0%
	% within Mual		85.7%	98.8%	96.9%
	% of Total		12.2%	84.7%	96.9%
>5 hari	Count		2	1	3
	% within Lama Penggunaan		66.7%	33.3%	100.0%
	% within Mual		14.3%	1.2%	3.1%
	% of Total		2.0%	1.0%	3.1%
Total	Count		14	84	98
	% within Lama Penggunaan		14.3%	85.7%	100.0%
	% within Mual		100.0%	100.0%	100.0%
	% of Total		14.3%	85.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	6.935 ^a	1	.008	.053	.053
Continuity Correction ^b	3.224	1	.073		
Likelihood Ratio	4.492	1	.034		
Fisher's Exact Test					
Linear-by-Linear Association	6.864	1	.009		
N of Valid Cases	98				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .43.

b. Computed only for a 2x2 table

Lama Penggunaan * Muntah

Crosstab

			Muntah		Total
			Ya	Tidak	
Lama Penggunaan	≤5 hari	Count	27	68	95
		% within Lama Penggunaan	28.4%	71.6%	100.0%
		% within Muntah	90.0%	100.0%	96.9%
		% of Total	27.6%	69.4%	96.9%
	>5 hari	Count	3	0	3
		% within Lama Penggunaan	100.0%	0.0%	100.0%
		% within Muntah	10.0%	0.0%	3.1%
		% of Total	3.1%	0.0%	3.1%
Total	Count	30	68	98	
	% within Lama Penggunaan	30.6%	69.4%	100.0%	
	% within Muntah	100.0%	100.0%	100.0%	
	% of Total	30.6%	69.4%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	7.015 ^a	1	.008	.027	.027
Continuity Correction ^b	4.050	1	.044		
Likelihood Ratio	7.320	1	.007		
Fisher's Exact Test					
Linear-by-Linear Association	6.943	1	.008		
N of Valid Cases	98				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .92.

b. Computed only for a 2x2 table

Lama Penggunaan * Pusing

Crosstab

			Pusing		Total
			Ya	Tidak	
Lama Penggunaan	≤5 hari	Count	18	77	95
		% within Lama Penggunaan	18.9%	81.1%	100.0%
		% within Pusing	90.0%	98.7%	96.9%
		% of Total	18.4%	78.6%	96.9%
	>5 hari	Count	2	1	3
		% within Lama Penggunaan	66.7%	33.3%	100.0%
		% within Pusing	11.1%	12.5%	23.8%
		% of Total	2.0%	1.1%	3.1%

	% within Lama Penggunaan	66.7%	33.3%	100.0%
	% within Pusing	10.0%	1.3%	3.1%
	% of Total	2.0%	1.0%	3.1%
Total	Count	20	78	98
	% within Lama Penggunaan	20.4%	79.6%	100.0%
	% within Pusing	100.0%	100.0%	100.0%
	% of Total	20.4%	79.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	4.077 ^a	1	.043	.105	.105
Continuity Correction ^b	1.668	1	.196		
Likelihood Ratio	3.121	1	.077		
Fisher's Exact Test					
Linear-by-Linear Association	4.035	1	.045		
N of Valid Cases	98				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .61.

b. Computed only for a 2x2 table

Lama Penggunaan * Kambung

Crosstab

			Kambung		Total
			Ya	Tidak	
Lama Penggunaan	≤5 hari	Count	17	78	95
		% within Lama Penggunaan	17.9%	82.1%	100.0%
		% within Kambung	89.5%	98.7%	96.9%
		% of Total	17.3%	79.6%	96.9%
	>5 hari	Count	2	1	3
		% within Lama Penggunaan	66.7%	33.3%	100.0%
		% within Kambung	10.5%	1.3%	3.1%
		% of Total	2.0%	1.0%	3.1%
Total		Count	19	79	98
		% within Lama Penggunaan	19.4%	80.6%	100.0%
		% within Kambung	100.0%	100.0%	100.0%
		% of Total	19.4%	80.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	4.426 ^a	1	.035	.095	.095
Continuity Correction ^b	1.856	1	.173		
Likelihood Ratio	3.312	1	.069		
Fisher's Exact Test					
Linear-by-Linear Association	4.381	1	.036		
N of Valid Cases	98				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .58.

b. Computed only for a 2x2 table

